Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
101 hedge funds and large institutions have $236M invested in Catalyst Pharmaceutical in 2019 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 38 increasing their positions, 20 reducing their positions, and 14 closing their positions.
107% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 14
90% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 20
15% more funds holding
Funds holding: 88 → 101 (+13)
0.1% less ownership
Funds ownership: 59.95% → 59.85% (-0.1%)
25% less capital invested
Capital invested by funds: $314M → $236M (-$77.9M)
43% less call options, than puts
Call options by funds: $981K | Put options by funds: $1.71M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$15M |
| 2 |
BlackRock
New York
|
+$4.71M |
| 3 |
AI
Atom Investors
Austin,
Texas
|
+$3.15M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$1.7M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$1.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$13.4M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$9.31M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$5.1M |
| 4 |
HRCM
Hawk Ridge Capital Management
Los Angeles,
California
|
-$3.34M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$2.54M |
CPRX Hedge Fund Activity: Q2 2019 in Review
101 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2019, worth a combined $236M — down 25% from $314M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CPRX positions and 14 closed out — a net gain of 15 holders — while 38 added to existing stakes and 20 trimmed.
The largest buyer was Armistice Capital, adding an estimated $15M. The largest seller was Broadfin Capital, cutting an estimated $13.4M.
- 101 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2019, up from 88 in Q1 2019.
- Funds reported $236M of Catalyst Pharmaceutical stock for Q2 2019, down 25% quarter-over-quarter.
- 29 funds opened new Catalyst Pharmaceutical positions in Q2 2019 and 14 closed out, a net change of +15 holders.
- The largest Catalyst Pharmaceutical buyer in Q2 2019 was Armistice Capital, an estimated $15M added.
- The largest Catalyst Pharmaceutical seller in Q2 2019 was Broadfin Capital, an estimated $13.4M sold.
Based on aggregated 13F filings for Q2 2019.